News coverage about Horizon Therapeutics (NASDAQ:HPTX) has trended somewhat positive recently, according to Accern. The research group ranks the sentiment of press coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Horizon Therapeutics earned a daily sentiment score of 0.12 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.4735751788501 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of Horizon Therapeutics (NASDAQ:HPTX) traded up 0% during midday trading on Thursday, hitting $46. The firm’s 50 day moving average price is $46.00 and its 200-day moving average price is $46.00. Horizon Therapeutics has a 1-year low of $46.00 and a 1-year high of $46.00.
COPYRIGHT VIOLATION NOTICE: “Horizon Therapeutics (NASDAQ:HPTX) Earning Somewhat Favorable Press Coverage, Study Finds” was originally published by Ticker Report and is owned by of Ticker Report. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/2799004/horizon-therapeutics-nasdaqhptx-earning-somewhat-favorable-press-coverage-study-finds.html.
Horizon Therapeutics Company Profile
Horizon Therapeutics, Inc, formerly Hyperion Therapeutics, Inc, is a biopharmaceutical company. The Company is engaged in the development and commercialization of therapeutics to treat disorders in the areas of orphan diseases. The Company’s products include RAVICTI (glycerol phenylbutyrate) oral liquid, BUPHENYL and AMMONAPS (sodium phenylbutyrate) tablets and powder.
Receive News & Ratings for Horizon Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.